IBRX
ImmunityBio, Inc. NASDAQ Listed Jul 28, 2015$7.75
After hrs
$8.48
-0.35%
Mkt Cap $8.0B
52w Low $1.91
55.6% of range
52w High $12.43
50d MA $7.99
200d MA $4.38
P/E (TTM)
-18.7x
EV/EBITDA
-11.7x
P/B
—
Debt/Equity
-1.8x
ROE
70.2%
P/FCF
-5.9x
RSI (14)
—
ATR (14)
—
Beta
0.06
50d MA
$7.99
200d MA
$4.38
Avg Volume
27.7M
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
3530 John Hopkins Court · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 23, 2026 | AMC | -0.08 | -0.06 | +25.0% | 9.83 | +3.3% | +17.5% | -3.0% | -2.8% | -0.5% | +6.2% | — |
| Nov 4, 2025 | AMC | -0.10 | -0.07 | +30.0% | 2.08 | +5.3% | +3.4% | +1.9% | +2.4% | +3.8% | +2.9% | — |
| Aug 5, 2025 | AMC | -0.10 | -0.10 | +0.0% | 2.41 | +0.4% | -1.2% | -0.4% | +1.2% | +2.5% | +2.5% | — |
| May 12, 2025 | AMC | -0.12 | -0.15 | -25.0% | 2.36 | +2.5% | +6.4% | +5.5% | +13.1% | +20.3% | +18.6% | — |
| Mar 3, 2025 | AMC | -0.26 | -0.15 | +42.3% | 2.85 | -1.8% | +6.0% | +7.4% | +4.9% | +5.3% | +2.1% | — |
| Nov 12, 2024 | AMC | -0.18 | -0.14 | +22.2% | 4.95 | +0.6% | -2.4% | -1.6% | -9.3% | +1.2% | +8.1% | — |
| Aug 12, 2024 | AMC | -0.17 | -0.20 | -17.6% | 4.42 | -0.2% | -14.9% | -12.2% | -10.0% | -9.3% | -9.5% | — |
| May 9, 2024 | AMC | -0.16 | -0.20 | -25.0% | 8.06 | -2.2% | +0.7% | +7.1% | +4.2% | +0.5% | -3.8% | — |
| Mar 19, 2024 | AMC | -0.18 | -0.19 | -5.6% | 5.43 | +1.3% | +10.3% | +13.6% | +11.8% | +0.2% | -5.7% | — |
| Nov 8, 2023 | AMC | -0.27 | -0.19 | +29.6% | 3.43 | -2.3% | -17.1% | -9.3% | +0.3% | +5.8% | +19.2% | — |
| Aug 8, 2023 | AMC | -0.26 | -0.28 | -7.7% | 1.86 | -0.5% | -10.2% | -6.5% | -1.6% | -0.5% | +5.4% | — |
| May 11, 2023 | AMC | -0.27 | -0.27 | +0.0% | 2.79 | +3.2% | -18.3% | +15.4% | +18.6% | +15.8% | +0.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 21 | D. Boral Capital | Maintains | Buy → Buy | — | $8.20 | $8.37 | +2.1% | -1.2% | -1.6% | -0.1% | -9.3% | -11.1% |
| Apr 8 | D. Boral Capital | Maintains | Buy → Buy | — | $6.86 | $7.30 | +6.4% | +1.7% | +9.0% | +6.1% | +6.4% | +10.8% |
| Mar 26 | D. Boral Capital | Maintains | Buy → Buy | — | $8.07 | $7.90 | -2.1% | -8.6% | -8.6% | -17.5% | -5.0% | -11.5% |
| Mar 23 | D. Boral Capital | Maintains | Buy → Buy | — | $8.47 | $8.54 | +0.8% | +11.0% | -12.4% | -4.7% | -12.9% | -12.9% |
| Mar 17 | D. Boral Capital | Maintains | Buy → Buy | — | $8.21 | $8.93 | +8.8% | +0.0% | +4.3% | +7.4% | +3.2% | +14.5% |
| Mar 9 | D. Boral Capital | Maintains | Buy → Buy | — | $8.67 | $8.29 | -4.4% | -2.5% | -7.6% | -4.6% | -9.8% | -3.2% |
| Mar 4 | Piper Sandler | Maintains | Overweight → Overweight | — | $10.00 | $9.45 | -5.5% | -10.0% | -10.4% | -13.3% | -15.5% | -19.9% |
| Feb 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.70 | $9.95 | +14.4% | +13.0% | +32.8% | +9.7% | +9.8% | +12.4% |
| Feb 23 | D. Boral Capital | Maintains | Buy → Buy | — | $8.70 | $9.95 | +14.4% | +13.0% | +32.8% | +9.7% | +9.8% | +12.4% |
| Feb 19 | D. Boral Capital | Maintains | Buy → Buy | — | $8.54 | $8.05 | -5.7% | +0.8% | +1.9% | +15.1% | +35.2% | +11.7% |
| Feb 17 | D. Boral Capital | Maintains | Buy → Buy | — | $5.95 | $6.26 | +5.2% | +1.2% | +43.5% | +44.7% | +46.2% | +65.2% |
| Jan 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.45 | $6.66 | +3.3% | -3.7% | -7.8% | -4.7% | -8.4% | -3.1% |
| Jan 23 | D. Boral Capital | Maintains | Buy → Buy | — | $7.34 | $7.38 | +0.5% | -12.1% | -15.4% | -18.9% | -16.2% | -19.5% |
| Jan 23 | BTIG | Maintains | Buy → Buy | — | $7.34 | $7.38 | +0.5% | -12.1% | -15.4% | -18.9% | -16.2% | -19.5% |
| Jan 20 | Piper Sandler | Maintains | Overweight → Overweight | — | $5.52 | $6.54 | +18.5% | +17.4% | +25.4% | +33.0% | +16.8% | +12.5% |
| Jan 20 | D. Boral Capital | Maintains | Buy → Buy | — | $5.52 | $6.54 | +18.5% | +17.4% | +25.4% | +33.0% | +16.8% | +12.5% |
| Jan 16 | D. Boral Capital | Maintains | Buy → Buy | — | $3.95 | $4.70 | +19.0% | +39.7% | +64.1% | +75.2% | +85.8% | +63.3% |
| Jan 13 | D. Boral Capital | Maintains | Buy → Buy | — | $2.59 | $2.68 | +3.5% | +8.9% | +16.6% | +52.5% | +113.1% | +150.2% |
| Dec 16 | D. Boral Capital | Maintains | Buy → Buy | — | $2.22 | $2.19 | -1.4% | -2.7% | -5.0% | -5.9% | -6.3% | +2.3% |
| Dec 12 | Jefferies | Maintains | Buy → Buy | — | $2.19 | $2.29 | +4.6% | +7.8% | +1.4% | -1.4% | -3.7% | -4.6% |
| Dec 12 | D. Boral Capital | Maintains | Buy → Buy | — | $2.19 | $2.29 | +4.6% | +7.8% | +1.4% | -1.4% | -3.7% | -4.6% |
| Dec 11 | D. Boral Capital | Maintains | Buy → Buy | — | $2.30 | $2.30 | +0.0% | -4.8% | +2.6% | -3.5% | -6.1% | -8.3% |
| Nov 13 | D. Boral Capital | Maintains | Buy → Buy | — | $2.06 | $2.03 | -1.5% | -2.9% | +1.0% | -1.5% | +1.9% | +3.9% |
| Nov 5 | D. Boral Capital | Maintains | Buy → Buy | — | $2.08 | $2.19 | +5.3% | +3.4% | +1.9% | +2.4% | +3.8% | +2.9% |
| Sep 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.57 | $2.56 | -0.4% | +0.0% | +0.8% | +1.2% | +6.6% | +9.3% |
| Sep 8 | D. Boral Capital | Maintains | Buy → Buy | — | $2.40 | $2.48 | +3.3% | +0.4% | +7.1% | +7.1% | +7.9% | +8.3% |
| Aug 26 | D. Boral Capital | Maintains | Buy → Buy | — | $2.25 | $2.37 | +5.3% | +5.8% | +4.0% | +3.6% | +4.0% | +5.8% |
| Aug 19 | D. Boral Capital | Maintains | Buy → Buy | — | $2.43 | $2.44 | +0.4% | -6.2% | -7.0% | -7.8% | -4.9% | -7.4% |
| Aug 14 | D. Boral Capital | Maintains | Buy → Buy | — | $2.82 | $2.76 | -2.1% | -3.9% | -9.6% | -13.8% | -19.1% | -19.9% |
| Aug 5 | D. Boral Capital | Maintains | Buy → Buy | — | $2.41 | $2.40 | -0.4% | +0.0% | -1.2% | -0.4% | +1.2% | +2.5% |
| Jul 25 | D. Boral Capital | Maintains | Buy → Buy | — | $3.01 | $3.04 | +1.0% | -5.0% | -12.0% | -15.6% | -15.0% | -18.3% |
| Jul 8 | D. Boral Capital | Maintains | Buy → Buy | — | $2.72 | $2.76 | +1.5% | -0.4% | +2.6% | +5.5% | +3.3% | +6.6% |
| Jun 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.71 | $2.75 | +1.5% | +8.1% | +7.0% | +16.2% | +26.9% | +23.2% |
| Jun 3 | D. Boral Capital | Maintains | Buy → Buy | — | $2.67 | $2.73 | +2.2% | +1.5% | +9.7% | +8.6% | +18.0% | +28.8% |
| May 28 | D. Boral Capital | Maintains | Buy → Buy | — | $2.53 | $2.52 | -0.4% | -2.8% | +2.8% | +5.1% | +5.5% | +7.1% |
| May 20 | Piper Sandler | Upgrade | Neutral → Overweight | — | $2.80 | $2.89 | +3.2% | +3.6% | -5.4% | -4.3% | -9.6% | -9.6% |
| May 12 | D. Boral Capital | Maintains | Buy → Buy | — | $2.07 | $2.26 | +9.2% | +14.0% | +21.3% | +20.3% | +29.0% | +37.2% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.07 | $2.26 | +9.2% | +14.0% | +21.3% | +20.3% | +29.0% | +37.2% |
| Apr 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.61 | $2.65 | +1.5% | +0.8% | -4.6% | -3.8% | -4.6% | -2.7% |
| Apr 28 | D. Boral Capital | Maintains | Buy → Buy | — | $2.61 | $2.65 | +1.5% | +0.8% | -4.6% | -3.8% | -4.6% | -2.7% |
| Apr 23 | D. Boral Capital | Maintains | Buy → Buy | — | $2.69 | $2.80 | +4.1% | +0.0% | +0.0% | -3.0% | -2.2% | -7.4% |
| Apr 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.78 | $2.73 | -1.8% | -10.8% | -11.2% | -9.7% | -3.2% | -3.2% |
| Apr 15 | D. Boral Capital | Maintains | Buy → Buy | — | $2.89 | $2.97 | +2.8% | -3.8% | -14.2% | -14.5% | -13.1% | -6.9% |
| Apr 9 | D. Boral Capital | Maintains | Buy → Buy | — | $2.42 | $2.43 | +0.4% | +7.4% | +1.7% | +8.7% | +19.4% | +14.9% |
| Mar 31 | D. Boral Capital | Maintains | Buy → Buy | — | $3.14 | $3.11 | -1.0% | -4.1% | -5.7% | -2.9% | -5.4% | -9.9% |
| Mar 13 | D. Boral Capital | Maintains | Buy → Buy | — | $2.87 | $2.84 | -1.0% | +1.0% | +0.0% | +1.4% | -2.1% | -3.8% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.87 | $2.84 | -1.0% | +1.0% | +0.0% | +1.4% | -2.1% | -3.8% |
| Mar 3 | D. Boral Capital | Maintains | Buy → Buy | — | $3.29 | $3.20 | -2.7% | -13.4% | -8.2% | -7.0% | -9.1% | -8.8% |
| Feb 28 | D. Boral Capital | Maintains | Buy → Buy | — | $2.86 | $3.12 | +9.1% | +15.0% | -0.3% | +5.6% | +7.0% | +4.5% |
| Feb 19 | D. Boral Capital | Maintains | Buy → Buy | — | $3.35 | $3.40 | +1.5% | +16.4% | +8.7% | +2.1% | -3.9% | -9.6% |
No insider trades available.
8-K · 2.02
!! High
ImmunityBio, Inc. -- 8-K 2.02: Earnings Results
ImmunityBio reported quarterly earnings results, with detailed financial performance metrics available in the attached press release exhibit.
May 7
8-K
Unknown — 8-K Filing
I cannot provide a meaningful analysis because the filing excerpt is incomplete and contains only boilerplate legal language about liability disclaimers and exhibit descriptions, with no substantive business information disclosed.
Apr 9
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
IBRX submitted a comprehensive FDA response, likely advancing its immunotherapy candidate toward potential approval, which could significantly de-risk the pipeline and drive stock upside if successful.
Apr 6
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Financing / Debt Agreement
IBRX secured $375 million in new financing, strengthening its balance sheet and providing capital for operations or acquisitions, which reduces near-term bankruptcy risk and supports growth initiatives.
Mar 31
8-K
ImmunityBio, Inc. -- 8-K Filing
I cannot provide a meaningful analysis as the summary contains only signature block information without substantive deal or business information.
Feb 23
8-K · 8.01
!! High
ImmunityBio, Inc. -- 8-K 8.01: Material Event / Announcement
ImmunityBio received European Commission authorization for ANKTIVA with BCG to treat non-muscle invasive bladder cancer, expanding product access across 33 countries and strengthening its commercial footprint.
Feb 18
Data updated apr 25, 2026 2:47pm
· Source: massive.com